References
Abdulqawi R, Dockry R, Holt K, Layton
G, McCarthy BG, Ford AP, et al. (2015). P2X3 receptor antagonist
(AF-219) in refractory chronic cough: a randomised, double-blind,
placebo-controlled phase 2 study. Lancet 385: 1198-1205.
Angelo R, Rousseau K, Grant M,
Leone-Bay A, & Richardson P (2009). Technosphere® insulin: Defining the
role of Technosphere particles at the cellular level. J Diabetes Sci
Technol 3: 545-554.
Backman P, Adelmann H, Petersson G, &
Jones CB (2014). Advances in inhaled technologies: understanding the
therapeutic challenge, predicting clinical performance, and designing
the optimal inhaled product. Clin Pharmacol Ther 95: 509-520.
Barker AF, Couch L, Fiel SB, Gotfried
MH, Ilowite J, Meyer KC, et al. (2000). Tobramycin solution for
inhalation reduces sputum Pseudomonas aeruginosa density in
bronchiectasis. Am J Respir Crit Care Med 162: 481-485.
Bilton D, Robinson P, Cooper P,
Gallagher CG, Kolbe J, Fox H, et al. (2011). Inhaled dry powder
mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J
38: 1071-1080.
Birrell MA, Bonvini SJ, Dubuis E,
Maher SA, Wortley MA, Grace MS, et al. (2014). Tiotropium
modulates transient receptor potential V1 (TRPV1) in airway sensory
nerves: A beneficial off-target effect? J Allergy Clin Immunol
133: 679-687.e679.
Birring SS, Wijsenbeek MS, Agrawal S,
van den Berg JWK, Stone H, Maher TM, et al. (2017). A novel
formulation of inhaled sodium cromoglicate (PA101) in idiopathic
pulmonary fibrosis and chronic cough: a randomised, double-blind,
proof-of-concept, phase 2 trial. Lancet Respir Med 5: 806-815.
Bonvini SJ, & Belvisi MG (2017).
Cough and airway disease: The role of ion channels. Pulm Pharmacol Ther
47: 21-28.
Brannan JD, Anderson SD, Perry CP,
Freed-Martens R, Lassig AR, Charlton B, et al. (2005). The safety
and efficacy of inhaled dry powder mannitol as a bronchial provocation
test for airway hyperresponsiveness: a phase 3 comparison study with
hypertonic (4.5%) saline. Respir Res 6: 144.
Brown PH, Lenney J, Armstrong S, Ning
AC, & Crompton GK (1992). Breath-actuated inhalers in chronic asthma:
comparison of Diskhaler and Turbohaler for delivery of beta-agonists.
Eur Respir J 5: 1143-1145.
Buday T, Kovacikova L, Ruzinak R, &
Plevkova J (2017). TRPV4 antagonist GSK2193874 does not modulate cough
response to osmotic stimuli. Respir Physiol Neurobiol 236: 1-4.
National Ambulatory Medical
Care Survey: 2010 Summary Tables [Online] Available from
https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2010_namcs_web_tables.pdf.
[Accessed: 7 Nov 2018].
Ceglia L, Lau J, & Pittas AG (2006).
Meta-analysis: efficacy and safety of inhaled insulin therapy in adults
with diabetes mellitus. Ann Intern Med 145: 665-675.
Challoner P, Flora M, Hirst P,
Klimowicz M, Newman S, Schaeffler B, et al. Gamma scintigraphy
lung deposition comparison of TOBI in the Pari LC Plus nebulizer and the
Aerodose inhaler.
Choudry NB, Fuller RW, & Pride NB
(1989). Sensitivity of the human cough reflex: effect of inflammatory
mediators prostaglandin E2, bradykinin, and histamine. Am Rev Respir Dis
140: 137-141.
Chung KF (2011). Chronic ’cough
hypersensitivity syndrome’: a more precise label for chronic cough. Pulm
Pharmacol Ther 24: 267-271.
Chung KF, & Pavord ID (2008).
Prevalence, pathogenesis, and causes of chronic cough. Lancet
371: 1364-1374.
Cipolla D, & Chan HK (2013). Inhaled
antibiotics to treat lung infection. Pharm Pat Anal 2: 647-663.
Conole D, & Keating GM (2014).
Colistimethate sodium dry powder for inhalation: a review of its use in
the treatment of chronic Pseudomonas aeruginosa infection in patients
with cystic fibrosis. Drugs 74: 377-387.
Corboz MR, Li Z, Malinin V, Plaunt
AJ, Konicek DM, Leifer FG, et al. (2017). Preclinical
pharmacology and pharmacokinetics of inhaled hexadecyl-treprostinil
(C16TR), a pulmonary vasodilator prodrug. J Pharmacol Exp Ther
363: 348-357.
de Marco R, Marcon A, Jarvis D,
Accordini S, Almar E, Bugiani M, et al. (2006). Prognostic
factors of asthma severity: a 9-year international prospective cohort
study. J Allergy Clin Immunol 117: 1249-1256.
Dharmadhikari AS, Kabadi M, Gerety B,
Hickey AJ, Fourie PB, & Nardell E (2013). Phase I, single-dose,
dose-escalating study of inhaled dry powder capreomycin: a new approach
to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother
57: 2613-2619.
Dubus JC, Mely L, Huiart L, Marguet
C, Le Roux P, & Reseau de Recherche Clinique en Pneumologie P (2003).
Cough after inhalation of corticosteroids delivered from spacer devices
in children with asthma. Fundam Clin Pharmacol 17: 627-631.
Elkins MR, Robinson M, Rose BR,
Harbour C, Moriarty CP, Marks GB, et al. (2006). A controlled
trial of long-term inhaled hypertonic saline in patients with cystic
fibrosis. N Engl J Med 354: 229-240.
Empey DW, Laitinen LA, Jacobs L, Gold
WM, & Nadel JA (1976). Mechanisms of bronchial hyperreactivity in
normal subjects after upper respiratory tract infection. Am Rev Respir
Dis 113: 131-139.
Engel T, Heinig JH, Malling HJ,
Scharling B, Nikander K, & Madsen F (1989). Clinical comparison of
inhaled budesonide delivered either via pressurized metered dose inhaler
or Turbuhaler. Allergy 44: 220-225.
Feldman DN, Fakorede F, Minutello RM,
Bergman G, Moussa I, & Wong SC (2010). Efficacy of high-dose
clopidogrel treatment (600 mg) less than two hours before percutaneous
coronary intervention in patients with non-ST-segment elevation acute
coronary syndromes. Am J Cardiol 105: 323-332.
Flume PA, Aitken ML, Bilton D, Agent
P, Charlton B, Forster E, et al. (2015). Optimising inhaled
mannitol for cystic fibrosis in an adult population. Breathe (Sheff)
11: 39-48.
Fuller RW, Dixon CM, & Barnes PJ
(1985). Bronchoconstrictor response to inhaled capsaicin in humans. J
Appl Physiol (1985) 58: 1080-1084.
Fuller RW, & Jackson DM (1990).
Physiology and treatment of cough. Thorax 45: 425-430.
Geller DE, Konstan MW, Smith J,
Noonberg SB, & Conrad C (2007). Novel tobramycin inhalation powder in
cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol
42: 307-313.
Geller DE, Nasr SZ, Piggott S, He E,
Angyalosi G, & Higgins M (2014). Tobramycin inhalation powder in cystic
fibrosis patients: response by age group. Respir Care 59:388-398.
Grace MS, Lieu T, Darby B, Abogadie
FC, Veldhuis N, Bunnett NW, et al. (2014). The tyrosine kinase
inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels
in vitro and pain in vivo. Br J Pharmacol 171: 3881-3894.
Greenwood J, Schwarz C, Sommerwerck
U, Nash EF, Tamm M, Cao W, et al. (2017). Ease of use of
tobramycin inhalation powder compared with nebulized tobramycin and
colistimethate sodium: a crossover study in cystic fibrosis patients
with pulmonary Pseudomonas aeruginosa infection. Ther Adv Respir Dis
11: 249-260.
Gziut M, MacGregor HJ, Nevell T,
Mason T, Laight D, & Shute JK (2013). Anti-inflammatory effects of
tobramycin and a copper-tobramycin complex with superoxide
dismutase-like activity. Br J Pharmacol 168: 1165-1181.
Hogg J (2004). Peripheral lung
remodelling in asthma and chronic obstructive pulmonary disease. Eur
Respir J 24: 893-894.
Hoppentocht M, Akkerman OW, Hagedoorn
P, Alffenaar JW, van der Werf TS, Kerstjens HA, et al. (2016).
Tolerability and pharmacokinetic evaluation of inhaled dry powder
tobramycin free base in non-cystic fibrosis bronchiectasis patients.
PLoS One 11: e0149768.
Hubert D, Leroy S, Nove-Josserand R,
Murris-Espin M, Mely L, Dominique S, et al. (2009).
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow
rapid nebulizer in cystic fibrosis. J Cyst Fibros 8: 332-337.
Huckle AW, Fairclough LC, & Todd I
(2018). Prophylactic antibiotic use in COPD and the potential
anti-inflammatory activities of antibiotics. Respir Care 63:609-619.
Irwin RS, French CL, Chang AB, Altman
KW, & Panel* CEC (2018). Classification of cough as a symptom in adults
and management algorithms: CHEST guideline and expert panel report.
Chest 153: 196-209.
Jansat JM, Lamarca R, de Miquel G,
Schrodter A, Miletzki B, & Gurniak M (2009). Safety and
pharmacokinetics of multiple doses of aclidinium bromide, a novel
long-acting muscarinic antagonist for the treatment of chronic
obstructive pulmonary disease, in healthy participants. J Clin Pharmacol
49: 1239-1246.
Johnstone KJ, Chang AB, Fong KM,
Bowman RV, & Yang IA (2013). Inhaled corticosteroids for subacute and
chronic cough in adults. Cochrane Database Syst Rev: CD009305.
Joos GF, De Swert KO, Schelfhout V,
& Pauwels RA (2003). The role of neural inflammation in asthma and
chronic obstructive pulmonary disease. Ann N Y Acad Sci 992:218-230.
Kamimura M, Izumi S, Hamamoto Y,
Morita A, Toyota E, Kobayashi N, et al. (2012). Superiority of
nebulized corticosteroids over dry powder inhalers in certain patients
with cough variant asthma or cough-predominant asthma. Allergol Int
61: 411-417.
Kanth PM, Alaienia C, & Smaldone GC
(2018). Nebulized mannitol, particle distribution, and cough in
idiopathic pulmonary fibrosis. Respir Care 63: 1407-1412.
Kingman M, Archer-Chicko C, Bartlett
M, Beckmann J, Hohsfield R, & Lombardi S (2017). Management of
prostacyclin side effects in adult patients with pulmonary arterial
hypertension. Pulm Circ 7: 598-608.
Konstan MW, Flume PA, Kappler M,
Chiron R, Higgins M, Brockhaus F, et al. (2011). Safety, efficacy
and convenience of tobramycin inhalation powder in cystic fibrosis
patients: The EAGER trial. J Cyst Fibros 10: 54-61.
Konstan MW, Geller DE, Minic P,
Brockhaus F, Zhang J, & Angyalosi G (2011). Tobramycin Inhalation
Powder for P. aeruginosa Infection in Cystic Fibrosis: The EVOLVE Trial.
Pediatr Pulmonol 46: 230-238.
Koskela HO, Lake C, Wong K, &
Brannan JD (2018). Cough sensitivity to mannitol inhalation challenge
identifies subjects with chronic cough. Eur Respir J 51.
Koskela HO, Purokivi MK, Kontra KM,
Taivainen AH, & Tukiainen HO (2008). Hypertonic saline cough
provocation test with salbutamol pre-treatment: evidence for
sensorineural dysfunction in asthma. Clin Exp Allergy 38:1100-1107.
Lavorini F, Magnan A, Dubus JC,
Voshaar T, Corbetta L, Broeders M, et al. (2008). Effect of
incorrect use of dry powder inhalers on management of patients with
asthma and COPD. Respir Med 102: 593-604.
Le Brun PP, de Boer AH, Mannes GP, de
Fraiture DM, Brimicombe RW, Touw DJ, et al. (2002a). Dry powder
inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation
of a novel colistin dry powder formulation: a feasibility study in
healthy volunteers and patients. Eur J Pharm Biopharm 54:25-32.
Le Brun PPH, de Boer AH, Mannes GPM,
de Fraı̂ture DMI, Brimicombe RW, Touw DJ, et al. (2002b). Dry
powder inhalation of antibiotics in cystic fibrosis therapy: part 2:
Inhalation of a novel colistin dry powder formulation: a feasibility
study in healthy volunteers and patients. Eur J Pharm Biopharm
54: 25-32.
Lenney W, Edenborough F, Kho P, &
Kovarik JM (2011). Lung deposition of inhaled tobramycin with eFlow
rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J
Cyst Fibros 10: 9-14.
Lin YW, Zhou Q, Onufrak NJ, Wirth V,
Chen K, Wang J, et al. (2017). Aerosolized polymyxin B for
treatment of respiratory tract infections: determination of
pharmacokinetic-pharmacodynamic indices for aerosolized polymyxin B
against Pseudomonas aeruginosa in a mouse lung infection model.
Antimicrob Agents Chemother 61.
Lowry RH, Wood AM, & Higenbottam TW
(1988). Effects of pH and osmolarity on aerosol-induced cough in normal
volunteers. Clin Sci (Lond) 74: 373-376.
Mazurek H, Chiron R, Kucerova T,
Geidel C, Bolbas K, Chuchalin A, et al. (2014). Long-term
efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic
fibrosis. Pediatr Pulmonol 49: 1076-1089.
Mazzone SB, & Undem BJ (2016). Vagal
afferent innervation of the airways in health and disease. Physiol Rev
96: 975-1024.
McLaughlin VV, Benza RL, Rubin LJ,
Channick RN, Voswinckel R, Tapson VF, et al. (2010). Addition of
inhaled treprostinil to oral therapy for pulmonary arterial
hypertension: a randomized controlled clinical trial. J Am Coll Cardiol
55: 1915-1922.
Midgren B, Hansson L, Karlsson JA,
Simonsson BG, & Persson CG (1992). Capsaicin-induced cough in humans.
Am Rev Respir Dis 146: 347-351.
Minasian C, Wallis C, Metcalfe C, &
Bush A (2008). Bronchial provocation testing with dry powder mannitol in
children with cystic fibrosis. Pediatr Pulmonol 43: 1078-1084.
Morice AH (2004). The diagnosis and
management of chronic cough. Eur Respir J 24: 481.
Morice AH, Faruqi S, Wright CE,
Thompson R, & Bland JM (2011). Cough hypersensitivity syndrome: a
distinct clinical entity. Lung 189: 73-79.
Morice AH, Kastelik JA, & Thompson R
(2001). Cough challenge in the assessment of cough reflex. Br J Clin
Pharmacol 52: 365-375.
Mutolo D, Cinelli E, Iovino L,
Pantaleo T, & Bongianni F (2016). Downregulation of the cough reflex by
aclidinium and tiotropium in awake and anesthetized rabbits. Pulm
Pharmacol Ther 38: 1-9.
Newhouse MT, Hirst PH, Duddu SP,
Walter YH, Tarara TE, Clark AR, et al. (2003). Inhalation of a
dry powder tobramycin PulmoSphere formulation in healthy volunteers.
Chest 124: 360-366.
Otterson GA, Villalona-Calero MA,
Sharma S, Kris MG, Imondi A, Gerber M, et al. (2007). Phase I
study of inhaled Doxorubicin for patients with metastatic tumors to the
lungs. Clin Cancer Res 13: 1246-1252.
Pilcer G, & Amighi K (2010).
Formulation strategy and use of excipients in pulmonary drug delivery.
Int J Pharm 392: 1-19.
Purokivi M, Koskela H, & Kontra K
(2013). Determinants of asthma control and quality of life in stable
asthma: evaluation of two new cough provocation tests. Clin Respir J
7: 253-260.
Quattrin T, Belanger A, Bohannon NJ,
Schwartz SL, & Exubera Phase IIISG (2004). Efficacy and safety of
inhaled insulin (Exubera) compared with subcutaneous insulin therapy in
patients with type 1 diabetes: results of a 6-month, randomized,
comparative trial. Diabetes Care 27: 2622-2627.
Richards R, Haas A, Simpson S,
Britten A, Renwick A, & Holgate S (1988). Effect of methacholine
induced bronchoconstriction on the pulmonary distribution and plasma
pharmacokinetics of inhaled sodium cromoglycate in subjects with normal
and hyperreactive airways. Thorax 43: 611-616.
Rosenstock J, Franco D, Korpachev V,
Shumel B, Ma Y, Baughman R, et al. (2015). Inhaled Technosphere
Insulin Versus Inhaled Technosphere Placebo in Insulin-Naive Subjects
With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes
Agents. Diabetes Care 38: 2274-2281.
Ryerson CJ, Abbritti M, Ley B,
Elicker BM, Jones KD, & Collard HR (2011). Cough predicts prognosis in
idiopathic pulmonary fibrosis. Respirology 16: 969-975.
Satia I, Badri H, Al-Sheklly B, Smith
JA, & Woodcock AA (2016). Towards understanding and managing chronic
cough. Clin Med (Lond) 16: s92-s97.
Scheinberg P, & Shore E (2005). A
pilot study of the safety and efficacy of tobramycin solution for
inhalation in patients with severe bronchiectasis. Chest 127:1420-1426.
Schuster A, Haliburn C, Doring G, &
Goldman MH (2013). Safety, efficacy and convenience of colistimethate
sodium dry powder for inhalation (Colobreathe DPI) in patients with
cystic fibrosis: a randomised study. Thorax 68: 344-350.
Shim C, & Williams MH, Jr. (1987a).
Cough and wheezing from beclomethasone aerosol. Chest 91:207-209.
Shim CS, & Williams MH, Jr. (1987b).
Cough and wheezing from beclomethasone dipropionate aerosol are absent
after triamcinolone acetonide. Ann Intern Med 106: 700-703.
Sommerwerck U, Virella-Lowell I,
Angyalosi G, Viegas A, Cao W, & Debonnett L (2016). Long-term safety of
tobramycin inhalation powder in patients with cystic fibrosis: phase IV
(ETOILES) study. Curr Med Res Opin 32: 1789-1795.
Sterling GM, & Batten JC (1969).
Effect of aerosol propellants and surfactants on airway resistance.
Thorax 24: 228-231.
Ternesten-Hasseus E, Johansson EL, &
Millqvist E (2015). Cough reduction using capsaicin. Respir Med
109: 27-37.
van den Borst B, Gosker HR, Zeegers
MP, & Schols AM (2010). Pulmonary function in diabetes: A metaanalysis.
Chest 138: 393-406.
Velkov T, Abdul Rahim N, Zhou QT,
Chan H-K, & Li J (2015). Inhaled anti-infective chemotherapy for
respiratory tract infections: Successes, challenges and the road ahead.
Adv Drug Deliv Rev 85: 65-82.
Westerman EM, De Boer AH, Le Brun
PPH, Touw DJ, Roldaan AC, Frijlink HW, et al. (2007). Dry powder
inhalation of colistin in cystic fibrosis patients: A single dose pilot
study. J Cyst Fibros 6: 284-292.
Westerman EM, Le Brun PPH, Touw DJ,
Frijlink HW, & Heijerman HGM (2004). Effect of nebulized colistin
sulphate and colistin sulphomethate on lung function in patients with
cystic fibrosis: a pilot study. J Cyst Fibros 3: 23-28.
Wex E, & Bouyssou T (2015).
Olodaterol attenuates citric acid-induced cough in naive and
ovalbumin-sensitized and challenged guinea pigs. PLoS One 10:e0119953.
Widdicombe JG (1995). Neurophysiology
of the cough reflex. Eur Respir J 8: 1193.
Williamson IJ, Matusiewicz SP, Brown
PH, Greening AP, & Crompton GK (1995). Frequency of voice problems and
cough in patients using pressurized aerosol inhaled steroid
preparations. Eur Respir J 8: 590-592.
Wong CH, & Morice AH (1999). Cough
threshold in patients with chronic obstructive pulmonary disease. Thorax
54: 62-64.
Zhou QT, Leung SS, Tang P,
Parumasivam T, Loh ZH, & Chan HK (2015). Inhaled formulations and
pulmonary drug delivery systems for respiratory infections. Adv Drug
Deliv Rev 85: 83-99.
Zwozdziaka A, Gini M, & Samek L
(2017). Implications of the aerosol size distribution modal structure of
trace and major elements on human exposure, inhaled dose and relevance
to the PM2.5 and PM10 metrics in a European pollution hotspot urban area
J Aerosol Sci 103: 38-52.